Cyrano Therapeutics said that the FDA has cleared the company's IND and that Cyrano now plans to move ahead with a Phase trial of CYR-064 nasal soft mist theophylline in patients who experienced hyposmia (loss of smell) following a viral infection. In December 2020, Cyrano announced that it had raised $12.8 million for a Phase 2 trial of CYR-064. The six-month trial … [Read more...] about Cyrano announces plans for Phase 2 trial of CYR-064 intranasal theophylline in patients with post-viral hyposmia
News
Adherium gets almost £500,000 from SBRI Healthcare for inhaler monitoring project
Adherium announced that it received an award of £499,871 for an inhaler monitoring project from Small Business Research Initiative (SBRI) Healthcare, a program from the UK's National Health Service. The project, titled "Smart Digital inhaler enabled asthma management in high-risk children aged 5 to 16 years managed in primary care to prevent asthma attacks," will … [Read more...] about Adherium gets almost £500,000 from SBRI Healthcare for inhaler monitoring project
Krystal Biotech’s KB407 inhaled gene therapy for CF gets EC orphan designation
According to Krystal Biotech, the European Commission has granted orphan designation to the company's KB407 inhaled gene therapy for the treatment of cystic fibrosis. The company said that KB407, which delivers two copies of the CFTR gene to the lungs via nebulization, also has received Orphan Drug designation from the FDA. In August 2022, Krystal announced plans … [Read more...] about Krystal Biotech’s KB407 inhaled gene therapy for CF gets EC orphan designation
Isterian Biotech to develop inhaled TG2 inhibitor for the treatment of IPF
Cambrian BioPharma announced that it has partnered with Aston University and Aston Professor Martin Griffin since 2019 on a startup called Isterian Biotech. According to the announcement, the company's pipeline features a transglutaminase 2 (TG2) inhibitor that has been shown to reduce lung fibrosis in a mouse model and which Isterian intends to develop as an inhaled … [Read more...] about Isterian Biotech to develop inhaled TG2 inhibitor for the treatment of IPF
FDA approves Avillion and AstraZeneca’s Airsupra (PT027) albuterol / budesonide MDI for the treatment of asthma
According to Avillion and AstraZeneca, the FDA has approved Airsupra (PT027) albuterol / budesonide MDI for the treatment of asthma in adults. Avillion partnered with AstraZeneca subsidiary Pearl Therapeutics on development of PT027 in 2018. In May 2022, the FDA accepted Avillion's NDA for Airsupra. The NDA sought approval for the inhaler's use as an asthma therapy by … [Read more...] about FDA approves Avillion and AstraZeneca’s Airsupra (PT027) albuterol / budesonide MDI for the treatment of asthma
Spexis reports results from Phase 1 trial of inhaled murepavadin
Spexis (formerly Polyphor) said that a Phase 1 study of inhaled murepavadin, which the company is developing for the treatment of P. aeruginosa lung infections, demonstrated that the inhaled formulation delivered via the PARI eFlow nebulizer was well tolerated at all dose levels and that concentrations of murepavadin in the lungs reached the desired levels while … [Read more...] about Spexis reports results from Phase 1 trial of inhaled murepavadin
Liquidia announces financing agreement for up to $100 million
Liquidia Corporation said that an investment by HealthCare Royalty (HCRx) of up to $100 million will support further clinical development and the potential launch of the company's Yutrepia treprostinil DPI. In return, HCRx will get tiered royalties on potential net revenue from Yutrepia and other Liquidia products in addition to fixed payments from Liquidia, with … [Read more...] about Liquidia announces financing agreement for up to $100 million
TFF Pharmaceuticals names Zamaneh Mikhak as Chief Medical Officer
TFF Pharmaceuticals, which is developing dry powder inhaled and nasal formulations based on its thin film freezing particle engineering technology, has announced the appointment of Zamaneh Mikhak as Chief Medical Officer. Mikhak was most recently Senior VP and Head of Clinical Development at Cogent Biosciences, and her prior industry experience includes roles at … [Read more...] about TFF Pharmaceuticals names Zamaneh Mikhak as Chief Medical Officer
ENA Respiratory gets $4.38 million from US Department of Defense for development of dry powder intranasal formulation of INNA-051
The US Department of Defense Chemical and Biological Defense Program (CBDP) has awarded Australian pharma company ENA Respiratory $4.38 million for development of a dry powder formulation of the company's INNA-051 intranasal pegylated TLR2/6 agonist for protection against a wide range of respiratory viruses, ENA said. According to ENA, the 12-month project is expected … [Read more...] about ENA Respiratory gets $4.38 million from US Department of Defense for development of dry powder intranasal formulation of INNA-051
Lupin launches Difizma triple combination DPI in India
Lupin announced that it has launched its Difizma indacaterol / glycopyrronium / mometasone DPI in India for the treatment of inadequately controlled asthma. The company says that Difizma is the first fixed dose combination approved for the treatment of poorly controlled asthma by the Drug Controller General of India (DCGI). In 2022, Glenmark launched an indacaterol … [Read more...] about Lupin launches Difizma triple combination DPI in India